**Supplementary Table 2.** Time to nadir.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Biomarker** | **Patients with some decline in bone marker (n (%))**  **N = 47** | | | **Median time to nadir (days) for patients with a bone marker decline** | | |
| **Enzalutamide**  **N = 12** | **Rad + Enza**  **N = 35** | **\* P-value** | **Enzalutamide** | **Rad + Enza** | **\*\* P-value** |
| BAP | 5 (42%) | 35 (100%) | <0.001 | 95 | 130 | 0.790 |
| CTP | 7 (58%) | 25 (71%) | 0.499 | 94 | 112 | 0.692 |
| P1NP | 7 (58%) | 33 (94%) | 0.008 | 85 | 112 | 0.871 |
| NTP | 7 (58%) | 30 (86%) | 0.098 | 83 | 164 | 0.176 |
| PYR | 5 (42%) | 17 (49%) | 0.714 | 83 | 133 | 0.465 |
| PSA | 7 (58%) | 28 (80%) | 0.240 | 167 | 180 | 0.483 |

\* Chi-square test was used to determine the p-values when comparing the proportions of patients with a baseline nadir by treatment arm with significance set at 0.05.

\*\* When calculating the median time to nadir, a subset of patients with some decline in bone marker was used. Wilcoxon rank sum test was used to calculate the p-value with significance set at 0.05.